JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients
The JUBILEE trial evaluates a novel treatment regimen combining metformin and sitagliptin (Janumet) followed by insulin glargine (Lantus) in Type 2 Diabetes Mellitus (T2DM) patients. This approach aims to enhance glycaemic control while minimizing hypoglycaemic events compared to traditional therapies involving sulfonylureas. Given the increasing prevalence of T2DM, particularly in Eastern populations, successful outcomes could position this regimen favorably in a competitive market dominated by established therapies. The trial's completion and results may influence prescribing patterns and market dynamics, particularly in regions with high T2DM incidence. Stakeholders should monitor the results for potential shifts in treatment guidelines and market access strategies.
Indication: Type 2 Diabetes Mellitus
Modality: small molecule
Target: Dipeptidyl Peptidase-4 (DPP-4) inhibition and insulin receptor activation.
Sponsor: Chinese University of Hong Kong
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Dipeptidyl Peptidase-4 (DPP-4) inhibition and insulin receptor activation.
View original source fields
Condition raw: Type 2 Diabetes Mellitus
Condition normalized: Type 2 Diabetes Mellitus
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dipeptidyl Peptidase-4 (DPP-4) inhibition and insulin receptor activation.
Target normalized: Dipeptidyl Peptidase-4 (DPP-4) inhibition and insulin receptor activation.